Plasma Alkylresorcinols Is an Objective Biomarker for Gluten Intake in Young Children
Artikel i vetenskaplig tidskrift, 2025

Background: Alkylresorcinols are a well-established biomarker for whole-grain intake. There is evidence suggesting that total plasma alkylresorcinol concentration may also be used as a biomarker for gluten intake in adults. Objectives: The aim of this study was to evaluate if total alkylresorcinol concentration is a valid biomarker for gluten intake in young children. Methods: Nonfasting plasma alkylresorcinol concentrations were analyzed by normal-phase ultrahigh-pressure liquid chromatography-tandem mass spectrometry in 65 children aged 18 mo included in a randomized controlled trial. The intervention group was following a gluten-free diet (n = 21, 31.3%), whereas the diet was unrestricted in the control group (n = 44, 65.7%). Alkylresorcinol concentrations in the 65 children were validated against simultaneously collected 3-d food records estimating total gluten intake. Results: Gluten intake in controls was median 5.8 grams/d (IQR: 2.8–9.4, max 17.1) compared with 0.0 g/d (IQR: 0.0–0.0, max 0.7, P < 0.001) in the intervention group. In the control group, wheat accounted for mean 85% (SD: 0.1) of the gluten intake. The intervention group had lower alkylresorcinol levels (median: 7.2 nmol/L; IQR: 4.0–10.5) compared with controls (median: 269; IQR: 116–505 nmol/L, P < 0.001). The correlation between alkylresorcinol concentrations and gluten intake was ρ = 0.68 (P < 0.001). Alkylresorcinol concentrations increased by 35.7% [95% confidence interval (CI): 25.9, 46.2, P < 0.001] for every g/d increase of gluten intake. The Cohen's weighted kappa between quartiles of alkylresorcinol and gluten intake was 0.73 (95% CI: 0.59, 0.86). Conclusions: Alkylresorcinol concentrations increased with gluten intake in young nonfasting children. The findings suggest that alkylresorcinol concentrations may be a useful biomarker for gluten intake in young children. This trial was registered at clinicaltrials.gov as NCT03562221.

children

clinical trial

alkylresorcinol

nonfasting

gluten

biomarker

Författare

Elin M.Hård af Segerstad

Skånes universitetssjukhus (SUS)

Oslo universitetssykehus

Lunds universitet

Emelie Ericson-Hallström

Lunds universitet

Anna Bokström

Skånes universitetssjukhus (SUS)

Lunds universitet

Marina Armeni

Chalmers, Life sciences, Systembiologi

Otto Savolainen

Chalmers, Life sciences, Infrastrukturer

Itä-Suomen Yliopisto

Carin Andrén Aronsson

Lunds universitet

Skånes universitetssjukhus (SUS)

Journal of Nutrition

0022-3166 (ISSN) 1541-6100 (eISSN)

Vol. 155 3 985-993

Ämneskategorier (SSIF 2025)

Pediatrik

Näringslära och dietkunskap

DOI

10.1016/j.tjnut.2025.01.020

PubMed

39880171

Mer information

Senast uppdaterat

2025-11-26